Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders

American Journal of Hematology

Volumn 69, Issue 3, 2002, Pages 185-191

  Jensen, Morten Krogh ^a   De Nully Brown, Peter ^a   Thorsen, Sixtus ^a   Hasselbalch, Hans Carl ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Anticardiolipin antibodies; Anticoagulant proteins; Chronic myeloproliferative disorders; Factor V Leiden

Indexed keywords

ANTICOAGULANT PROTEIN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; D DIMER; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOMODULIN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; FIBRINOLYSIS; GENE FREQUENCY; GENE MUTATION; HETEROZYGOTE; HUMAN; INCIDENCE; MALE; MYELOPROLIFERATIVE DISORDER; PARTIAL THROMBOPLASTIN TIME; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; VEIN THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTICARDIOLIPIN; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; ENDOTHELIUM, VASCULAR; FACTOR V; FEMALE; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; RISK FACTORS; THROMBOPHILIA;

EID: 0036176284     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10054     Document Type: Article

References (38)

1. Incidence, clinical features and outcome of essential thrombo-cythaemia in a well defined geographical area
2. Idiopathic myelofibrosis. A review
3. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders
4. Mechanisms of bleeding and thrombosis in myeloproliferative disorders
5. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count
6. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma
7. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia
8. Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: A rationale for the use of low-dose aspirin as an antithrombotic agent
9. Increased thromboxane biosynthesis in patients with polycythemia vera: Evidence for aspirin-suppressible platelet activation in vivo
10. Thrombosis and bleeding in myeloproliferative disorders: Identification of at-risk patients with whole blood platelet aggregation studies
11. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders
12. Increased circulating platelet- leucocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count
13. Platelet-leukocyte-endothelial interaction on the blood vessel wall
14. Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells
15. Activated platelets induce superoxide anion release by monocytes and neutrophils through P-selectin (CD62)
16. Induction of superoxide anion production from monocytes and neutrophils by activated platelets through the P-selectin-sialyl Lewis X interaction
17. Therapeutic recommendations in polycythemia vera based on polycythemia vera study group protocols
18. Essential thrombo-cythemia: An interim report from the polycythemia vera study group
19. Splice site mutation in the human protein C gene associated with venous thrombosis: Demonstration of exon skipping by ectopic transcript analysis
20. The specificity of anticardiolipin antibodies from syphilis patients and patients with systemic lupus erythematosus
21. Two mutations in exon XII of the protein Sα gene in four thrombophilic families resulting in premature stop codons and depressed levels of mutated mRNA
22. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated prothrombin levels and an increase in venous thrombosis
23. The Arg506Gln mutation (FV Leiden) among a cohort of 4,188 unselected Danish newborns
24. A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders
25. Enhanced generation of monocyte tissue factor and increased plasma prothrombin fragment 1 + 2 levels in patients with polycythemia vera
26. Hemostatic system activation in patients with lupus anticoagulant and essential thrombocythemia
27. Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation
28. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis
29. Low proteins C and S and activation of fibrinolysis in treated essential thrombocythemia
30. The fibrinolytic system and proteins C and S in treated polycythemia rubra vera
31. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA or vWF
32. Plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia and essential thrombocythemia are associated with thrombosis
33. Increased levels of the soluble adhesion molecule E-selectin in patients with chronic myeloproliferative disorders and thromboembolic complications
34. Resistance to activated protein C as a basis for venous thrombosis
35. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four-year prospective study from the Italian registry
36. The antiphospholipid syndrome: Ten years on
37. Recent insights into antiphospholipid antibody-mediated thrombosis
38. Antiphospholipid antibodies and essential thrombocythemia